Back to top
more

Enanta Pharmaceuticals (ENTA)

(Delayed Data from NSDQ)

$12.66 USD

12.66
254,121

+0.02 (0.16%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $12.68 +0.02 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sanghamitra Saha headshot

Play the Best Sector of Summer With These ETFs & Stocks

by Sanghamitra Saha

Health care is apparently one of the best-performing sectors of summer. So, track these ETFs and stocks.

    Zacks Equity Research

    Why Enanta Pharmaceuticals (ENTA) Could Shock the Market Soon

    by Zacks Equity Research

    Although overlooked by the investors, Enanta Pharmaceuticals (ENTA) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.

      Zacks Equity Research

      Bayer's Generic Competition, Pipeline Setback Issues Remain

      by Zacks Equity Research

      Generic threats/competition for many of its products remain a concern for Bayer (BAYRY).

        Zacks Equity Research

        Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y

        by Zacks Equity Research

        Dr. Reddy's bottom line and top line suffered a year-over-year decline, in the fourth quarter of fiscal 2018.

          Zacks Equity Research

          AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia

          by Zacks Equity Research

          AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.

            Zacks Equity Research

            Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study

            by Zacks Equity Research

            Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.

              Zacks Equity Research

              Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion

              by Zacks Equity Research

              Zoetis (ZTS) inks a definitive deal to acquire Caifornia-based Abaxis, for $83 per share in cash or a total of $2 billion.

                Zacks Equity Research

                Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study

                by Zacks Equity Research

                Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.

                  Zacks Equity Research

                  Roche's Actemra Gets FDA Nod for Subcutaneous Formulation

                  by Zacks Equity Research

                  FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.

                    Sweta Killa headshot

                    Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?

                    by Sweta Killa

                    Style Box ETF report for FYC